Table 2 Patients’ characteristics at the time of platinum-resistant recurrence

Time from diagnosis to platinum-resistant recurrence

0.441

 Median (range), months

9.7(3.0–86.1)

9.7(2.6–96.2)

Platinum-resistant type

0.286

 Primary platinum-resistant disease

12(60.0%)

23(74.2%)

 Platinum-sensitive at first relapse

8(40.0%)

8(25.8%)

Number of recurrences before platinum-resistant (n,%)

0.346

 0

12(60.0%)

23(74.2%)

 1

5(25.0%)

4(12.9%)

 2

2(10.0%)

4(12.9%)

 3

1(5.0%)

0(0)

Number of surgeries before platinum-resistant (including primary surgery)

0.668

 1

16(80.0%)

25(80.6%)

 2

3(15.0%)

6(19.4%)

 4

1(5.0%)

0(0)

CA125, median (range), U/ml

75.9 (3.7–1000.0)

169.3(6.8–5000.0)

0.213

Ascites at recurrence

0.486

 Absent

19(95.0%)

28(90.3%)

 Present

1(5.0%)

3(9.7%)

Pattern of recurrence

0.471

 Only peritoneum^a

14(70.0%)

21(67.7%)

 Only limphnode^b

1(5.0%)

3(9.7%)

 Only parenchyma^c

0(0)

3(9.7%)

 Mixed

5(25.0%)

4(12.9%)

 Mixed exclude lymph node

0(0)

2(6.5%)

 Mixed exclude parenchyma

3(15.0%)

2(6.5%)

Extra-abdominal recurrence

0.287

 Absent

17(85.0%)

30(96.8%)

 Present

3(15.0%)

1(3.2%)

Maximum recurrent lesion size, median(range), cm

3.0(2.0-7.0)

3.0(0.9-7.0)

0.398

Platinum re-treated after platinum resistance

0.193

 Yes

10(50.0%)

11(35.5%)

 No

9(45.0%)

20(64.5%)

 No-chemotherapy

1(5.0%)

0(0%)

BRCA mutation

0.263

 Yes

5(25.0%)

3(9.7%)

 No

3(15.0%)

9(29.0%)

 Missing

12(60.0%)

19(61.3%)

HRD status

0.474

 Positive

6(30.0%)

5(16.1%)

 Negative

0(0)

1(3.2%)

 Missing

14(70.0%)

25(80.6%)

Maintenance treatment

-

 First-line maintenance therapy only

1(5.0%)

2(6.5%)

 Maintenance therapy after recurrence only

6(30.0%)

8(25.8%)

 Both

1(5.0%)

2(6.5%)

 PARPi after PARPi

1(5.0%)

1(3.2%)